UBS: Resumes Coverage on Regeneron Pharmaceuticals (REGN.US) with "Buy" Rating, Undervalues the Potential of Blockbuster Drug Dupixent
智通财经2026/10/15 06:46Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
Zhihu Finance APP has learned that UBS has resumed coverage of Regeneron Pharmaceuticals (REGN.US) with a “Buy” rating and a target price of $978, which is about 30% higher than the latest closing price. Previously, the bank had assigned a “Neutral” rating to the stock.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
U.S. stocks move: SanDisk plunges on October 15—CPI heats up, AI concerns, and sell-off in storage stocks
Bitget异动解读•2026/10/15 08:15
Barclays raises ASML's target price to 2,500 euros
智通财经•2026/10/15 08:11
Crypto prices
More
Bitcoin
BTC
$81,203.33
-3.00%
Ethereum
ETH
$2,372.04
-5.58%
Tether USDt
USDT
$0.9986
-0.02%
BNB
BNB
$720.45
-3.14%
XRP
XRP
$1.31
-4.71%
USDC
USDC
$0.9998
+0.00%
Solana
SOL
$102.94
-4.43%
TRON
TRX
$0.3320
+0.00%
Hyperliquid
HYPE
$80.18
-2.04%
Zcash
ZEC
$1,104.54
-11.88%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now